14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Clinical significance of expression levels of serum ADRA1A in hysterocarcinoma patients

      research-article
      1 , 2 , 1 , 1
      Oncology Letters
      D.A. Spandidos
      serum ADRA1A, hysterocarcinoma patients

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The clinical significance of the expression level of serum adrenergic receptor α1 (ADRA1A) in hysterocarcinoma patients was determined. Peripheral serum samples were collected at the Hubei Cancer Hospital from 455 patients affected by hysterocarcinoma and 380 healthy adults, who served as the normal control group. We determined the expression levels of ADRA1A by ELISA and analyzed its correlation to clinical features and prognosis of the patients. Compared with the normal control group, the expression of ADRA1A in the average peripheral serum level of hysterocarcinoma patients was clearly increased (P<0.05). In addition, the expression level of ADRA1A was positively correlated with the FIGO staging for hysterocarcinoma (r=0.312, P=0.014). Furthermore, the expression levels of serum ADRA1A in patients with metastasis were significantly increased compared to the levels of hysterocarcinoma patients without metastasis (P<0.05). Our analyses also showed that the expression levels of serum ADRA1A in hysterocarcinoma patients did not correlate with patient factors such as age, tumor invasive depth, tumor size or tumor differentiation degree (P>0.05). The Kaplan-Meier survival analysis indicated that the median survival time (37.1 months) of patients with a high expression of serum ADRA1A was lower than that of patients with a low expression of serum ADRA1A (68 months) (P<0.05). The three- and five-year survival rates of patients expressing low serum ADRA1A were, respectively, 74.00 and 62.00%; and the three- and five-year survival rates of patients expressing high levels of serum ADRA1A were 52.00 and 32.00%, respectively, with all the differences being statistically significant (P<0.05). ADRA1A was highly expressed in the peripheral serum in patients with hysterocarcinoma and the expression of ADRA1A was associated with FIGO staging and lymph node metastasis status. The expression of serum ADRA1A can be used to assess the survival rate and may be involved in the pathogenesis and metastasis progression of hysterocarcinoma.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Robotic radical hysterectomy in early stage cervical cancer: A systematic review and meta-analysis.

          To compare intraoperative and short-term postoperative outcomes of robotic radical hysterectomy (RRH) to laparoscopic and open approaches in the treatment of early stage cervical cancer.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Implementation of 'see-and-treat' cervical cancer prevention services linked to HIV care in Zambia.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy.

              The aim of the present study was to evaluate the outcome of patients with stage lb-IIb cervical adenocarcinoma treated with radical hysterectomy, and to determine the clinicopathological characteristics of those patients. A total of 255 patients with cervical carcinoma stage Ib-IIb (57 adenocarcinoma and 198 squamous cell carcinoma) who had undergone radical hysterectomy were included in this study. Patient survival distribution was calculated using the Kaplan-Meier method. The estimated 5-year survival rate for patients with adenocarcinoma was significantly poorer than that for patients with squamous cell carcinoma (77.9% vs 91.7%). The survival rate in stage Ib patients did not differ between two groups (95.8% vs 94.4% respectively). The incidence of lymph node involvement was significantly higher in patients with adenocarcinoma than in those with squamous cell carcinoma (31.6% vs 14.8%). Among patients receiving post-operative radiotherapy, the survival rate for adenocarcinoma (71.1%) was significantly poorer than that for squamous cell carcinoma (90.0%). When patients underwent radical hysterectomy, the survival rate for stage II patients with adenocarcinoma was significantly poorer than that for patients with squamous cell carcinoma. The higher incidence of lymph node involvement and lower response to post-operative radiotherapy are considered to be factors of poorer prognosis in cervical adenocarcinoma.
                Bookmark

                Author and article information

                Journal
                Oncol Lett
                Oncol Lett
                OL
                Oncology Letters
                D.A. Spandidos
                1792-1074
                1792-1082
                June 2018
                11 April 2018
                11 April 2018
                : 15
                : 6
                : 9162-9166
                Affiliations
                [1 ]Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, Hubei 430070, P.R. China
                [2 ]Department of Radiology, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China
                Author notes
                Correspondence to: Dr Hui-Feng Zhang, Department of Gynecologic Oncology, Hubei Cancer Hospital, 116 Zhuodaoquan South Road, Wuhan, Hubei 430070, P.R. China, E-mail: efzi_388634@ 123456163.com
                Article
                OL-0-0-8465
                10.3892/ol.2018.8465
                5958733
                29805646
                6895ade5-198c-4623-ab6f-650de59b4572
                Copyright: © Peng et al.

                This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

                History
                : 16 August 2017
                : 18 January 2018
                Categories
                Articles

                Oncology & Radiotherapy
                serum adra1a,hysterocarcinoma patients
                Oncology & Radiotherapy
                serum adra1a, hysterocarcinoma patients

                Comments

                Comment on this article